About AsthernaASTHERNA is a RNA therapy company developing a treatment for Stargardt disease, an inherited progressive retinal disorder, affecting hundred thousand individuals worldwide. For several genetic defects that cause this disease, we have developed a unique therapeutic approach with which we aim to stop the progression of the disease, and prevent individuals from getting blind. Astherna aims to develop therapeutic molecules, demonstrate efficacy and safety, in order to maximize the impact of our therapeutic solution on patient’s lives.
- CEO: Joram Sjoerts a.i.
- Affliated department: Ophthalmology
- Researchers: Rob Collin & Carel Hoyng
- Year of incorporation: 2021